<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372137</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXH94C001</org_study_id>
    <secondary_id>2011-000705-46</secondary_id>
    <nct_id>NCT01372137</nct_id>
  </id_info>
  <brief_title>First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94</brief_title>
  <official_title>First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOXXON Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOXXON Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first clinical trial with NOX-H94. The purpose of this clinical trial is to&#xD;
      identify a safe and efficacious treatment regimen for the clinical development of NOX-H94 in&#xD;
      patients with anemia of chronic disease (inflammation).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOX H94 is a pegylated Spiegelmer that specifically binds to human hepcidin, thereby&#xD;
      antagonizing its role in hemostasis, and is therefore indicated for use in anemia of&#xD;
      inflammation. Human hepcidin has emerged as the central regulatory molecule of systemic iron&#xD;
      homeostasis. Hepcidin expression in hepatocytes is regulated by multiple, in particular&#xD;
      opposing signals, including systemic iron availability, hepatic iron stores, erythropoietic&#xD;
      activity, hypoxia, and inflammatory states. These different signals are integrated&#xD;
      transcriptionally. In chronic inflammation, such as occurs in rheumatoid arthritis, chronic&#xD;
      kidney disease or cancer, elevated hepcidin levels have been measured and may be a key factor&#xD;
      leading to anemia in these patients.&#xD;
&#xD;
      NOX-H94 is therefore indicated for treatment of patients with an anemia of inflammation,&#xD;
      which is characterized by increased intracellular iron stores, increased serum ferritin&#xD;
      concentrations and reduced sensitivity to treatment with erythropoiesis stimulating agents&#xD;
      (ESAs), due to the limited availability of serum iron. Antagonism of hepcidin by NOX-H94&#xD;
      therefore leads to elevated levels of iron and transferrin saturation in the peripheral blood&#xD;
      and could supply iron for erythropoiesis thereby correcting the anemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>0 to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>drug plasma concentrations</measure>
    <time_frame>0 to 29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Anemia</condition>
  <condition>Chronic Diseases</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>NOX-H94</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose 5%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group A to Group H get NOX-H94 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-H94</intervention_name>
    <description>Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration</description>
    <arm_group_label>NOX-H94</arm_group_label>
    <other_name>lexaptepid pegol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose 5%</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Glucose 5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male subjects or female subjects of non-childbearing potential (Groups A to E), male&#xD;
             subjects (groups F to H)&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Healthy as determined by medical history, physical examination, vital signs, 12-lead&#xD;
             electrocardiogram, and clinical laboratory parameters&#xD;
&#xD;
          -  Males willing to use 2 means of contraceptive methods for at least 2 months after the&#xD;
             final examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anemia predominantly caused by other factors than chronic disease.&#xD;
&#xD;
          2. Iron overload or disturbances in utilization of iron.&#xD;
&#xD;
          3. Intravenous iron treatment or blood transfusion within 4 weeks prior to screening&#xD;
             visit.&#xD;
&#xD;
          4. Erythropoietin treatment within 4 weeks prior to screening visit.&#xD;
&#xD;
          5. Intake of Intravenous iron, Blood transfusions, Erythropoietin during their trial&#xD;
             participation.&#xD;
&#xD;
          6. Resting supine pulse rate &lt; 40 or &gt; 100 beats / min.&#xD;
&#xD;
          7. Resting supine blood pressure:&#xD;
&#xD;
             Systolic blood pressure &lt; 90 or &gt; 160 mmHg Diastolic blood pressure &lt; 40 or &gt; 100&#xD;
             mmHg.&#xD;
&#xD;
          8. History or presence of confirmed orthostatic hypotension defined.&#xD;
&#xD;
          9. Positive test of HIV type 1/2 antibodies, HBs antigen, HBc antibodies, HCV antibodies.&#xD;
&#xD;
         10. Participation in another clinical trial during the last 3 months before starting this&#xD;
             trial.&#xD;
&#xD;
         11. Positive test for drugs of abuse.&#xD;
&#xD;
         12. Diseases or condition known to interfere with the absorption, distribution, metabolism&#xD;
             or excretion of drugs.&#xD;
&#xD;
         13. Marked repolarization abnormality.&#xD;
&#xD;
         14. Current bronchial asthma, childhood asthma which has been resolved is allowed.&#xD;
&#xD;
         15. Definite or suspected history of drug allergy or hypersensitivity or intolerance to&#xD;
             PEG&#xD;
&#xD;
         16. Regular intake of over 14 units of alcohol per week for women and 21 units for men.&#xD;
&#xD;
         17. Not able to abstain from consumption of:&#xD;
&#xD;
               -  Caffeine containing beverages or food (tea, coffee, cola, chocolate, etc.)&#xD;
&#xD;
               -  Quinine containing beverages or food (bitter lemon, tonic water)&#xD;
&#xD;
               -  Grapefruit juice (sweet or sour)&#xD;
&#xD;
               -  Poppy seeds containing beverages or food&#xD;
&#xD;
         18. Subjects who have donated any blood, plasma or platelets in the month prior to&#xD;
             screening&#xD;
&#xD;
         19. History of seizures or at risk&#xD;
&#xD;
         20. Known or suspected of not being able to comply with the trial protocol and/or clinical&#xD;
             unit restrictions.&#xD;
&#xD;
         21. History of or presence of clinically significant diseases other than the underlying&#xD;
             disease.&#xD;
&#xD;
         22. Surgery or trauma with significant blood loss within the last 2 months before&#xD;
             administration of study drug.&#xD;
&#xD;
        28. History of increased bleeding risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riecke Kai, MD</last_name>
    <role>Study Director</role>
    <affiliation>NOXXON Pharma AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HMR</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NOX-H94</keyword>
  <keyword>Hepcidin</keyword>
  <keyword>Anemia</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_id>doi: 10.1111/bph.13433</doc_id>
      <doc_type>Manuscript</doc_type>
      <doc_url>http://onlinelibrary.wiley.com/doi/10.1111/bph.13433/abstract;jsessionid=E657A6C9667BB70DE92E5B69B86B1D3F.f01t01</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

